Hong Kong
Nuance Pharma announced that the National Medical Products Administration (NMPA) of China has officially accepted for review the New Drug Application (NDA)...
January 28, 2026 | News
-Topline data from the Phase II study for the treatment of diabetes are expected in the third quarter of 2026. -ASC30&n...
January 27, 2026 | News
AIM Vaccine (06660.HK), a leading domestic vaccine company, announced on January 15 that its research and development of the iterative process high-efficie...
January 19, 2026 | News
Marks a major milestone in Zylox-Tonbridge's long-term commitment to global expansion Builds an integrated global commercialization platform to accel...
January 19, 2026 | News
GenEditBio Limited ("GenEditBio"), a clinical-stage biotechnology startup focusing on genome-editing therapeutic solutions, today announced that the U.S. F...
January 06, 2026 | News
-The Phase II study for diabetes is a 13-week, randomized, double-blind, placebo-controlled and multi-center study to evaluate the effi...
January 06, 2026 | News
Marking a Key Milestone Toward Market Launch and Strengthening Sisram's Premium Aesthetics Portfolio Sisram Medical Ltd (the "Company...
January 06, 2026 | News
Insilico Medicine (3696.HK), a clinical-stage drug discovery and development company driven by generative artificial intelligence (AI), is successfully lis...
December 31, 2025 | News
In alignment with the national framework for the advancement of proton therapy, facilitated by the National Cancer Center, HKSH Medical Group ("HKSH")...
December 25, 2025 | News
Peijia Medical (9996.HK), a leading Chinese domestic company in the high-growth transcatheter valve therapeutics and neurovascular interventions markets, a...
December 16, 2025 | News
Akeso, Inc. (9926.HK) ("Akeso" or the "Company") announced FDA approval to initiate COMPASSION-37/AK104-311 trial, a global multicenter Phase III trial in ...
December 15, 2025 | News
Acquisition of Staccato® One Breath Technology®, a proprietary platform technology with broad therapeutic potential Synergistic and complementar...
December 11, 2025 | News
- XPOVIO® (selinexor) has received approvals for three indications in Hong Kong. These include its previous approval as the treatment for mul...
December 04, 2025 | News
Antengene Corporation Limited ("Antengene", SEHK: 6996.HK), a leading innovative, commercial-stage global biotech company dedicated to discovering, develop...
December 03, 2025 | News
Most Read
Bio Jobs
News
Editor Picks